Eli Lilly Says FDA OKs SBLA For Taltz Injection For Non-Radiographic Axial Spondyloarthritis

Eli Lilly and Co. (LLY) announced Monday that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz (ixekizumab) injection 80 mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation.

from RTT - Biotech https://ift.tt/36NvYrg
via IFTTT